Latest Breaking News On - நோவர்த்திச் நிறுவனங்கள் க்கு உயிர் மருத்துவ ஆராய்ச்சி - Page 11 : comparemela.com
Novartis Pharma AG: Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Michael S. Abrams its chief financial officer.
In alignment with the company’s succession plan, Abrams joins Arch’s financial team in the role previously held by Richard Davis. Davis will remain with the company during a transition period, which will end on June 30, after which he will support the company in a consulting role through Dec. 31.
Abrams has more than 25 years of experience as a chief financial officer to numerous public and private companies; principal investor; investment banker; merchant banker; strategic and financial adviser; and board member. His capabilities span a broad range of activities with a particular expertise in the areas of operational management, complex financial engineering, financial advisory and capital markets strategy primarily for companies in the technology and healthcare sectors.
Published: May 13, 2021 By Alex Keown
Akouos, Inc. – Kathy Reape was named chief development officer of Boston-based Akouos. Reape most recently served as chief medical officer at Spark Therapeutics where she oversaw clinical development, pharmacovigilance, and medical affairs activities. Reape was a key member of the team responsible for the development and commercialization of Luxturna, the first FDA-approved in vivo gene therapy approved for an inherited retinal disease caused by mutations in both copies of the RPE65 gene. Prior to Spark, Reape was senior vice president of clinical development focusing on global brands research and development at Allergan and Actavis.
CARMAT – France-based CARMAT’s board of directors is reorganizing its governance and appointed three new directors. The company tapped Florent Battistella, David Coti and John B. Hernandez as directors. Battistella founded Nisima, a holding company, which holds stakes in various firms, notably
vimarsana © 2020. All Rights Reserved.